Search details
1.
Delta-like ligand 3-targeted radioimmunotherapy for neuroendocrine prostate cancer.
Proc Natl Acad Sci U S A
; 119(27): e2203820119, 2022 07 05.
Article
in English
| MEDLINE | ID: mdl-35759660
2.
Development of a multigenomic liquid biopsy (PROSTest) for prostate cancer in whole blood.
Prostate
; 84(9): 850-865, 2024 Jun.
Article
in English
| MEDLINE | ID: mdl-38571290
3.
A Prognostic Risk Score for Prostate Cancer Based on PSMA PET-derived Organ-specific Tumor Volumes.
Radiology
; 307(4): e222010, 2023 05.
Article
in English
| MEDLINE | ID: mdl-37070991
4.
Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT).
Eur J Nucl Med Mol Imaging
; 50(9): 2830-2845, 2023 07.
Article
in English
| MEDLINE | ID: mdl-37246997
5.
Treatment Response and Clinical Outcomes of Well-Differentiated High-Grade Neuroendocrine Tumors to Lutetium-177-DOTATATE.
Neuroendocrinology
; 112(12): 1177-1186, 2022.
Article
in English
| MEDLINE | ID: mdl-35609558
6.
Imaging of Neuroendocrine Neoplasms: Monitoring Treatment Response-AJR Expert Panel Narrative Review.
AJR Am J Roentgenol
; 218(5): 767-780, 2022 05.
Article
in English
| MEDLINE | ID: mdl-34985313
7.
Treatment of advanced gastroenteropancreatic neuroendocrine neoplasia, are we on the way to personalised medicine?
Gut
; 70(9): 1768-1781, 2021 09.
Article
in English
| MEDLINE | ID: mdl-33692095
8.
177Lu-Dotatate plus long-acting octreotide versus highdose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial.
Lancet Oncol
; 22(12): 1752-1763, 2021 12.
Article
in English
| MEDLINE | ID: mdl-34793718
9.
Early Identification of Residual Disease After Neuroendocrine Tumor Resection Using a Liquid Biopsy Multigenomic mRNA Signature (NETest).
Ann Surg Oncol
; 28(12): 7506-7517, 2021 Nov.
Article
in English
| MEDLINE | ID: mdl-34008138
10.
Imaging and liquid biopsy in the prediction and evaluation of response to PRRT in neuroendocrine tumors: implications for patient management.
Eur J Nucl Med Mol Imaging
; 48(12): 4016-4027, 2021 11.
Article
in English
| MEDLINE | ID: mdl-33903926
11.
A simple strategy to reduce the salivary gland and kidney uptake of PSMA-targeting small molecule radiopharmaceuticals.
Eur J Nucl Med Mol Imaging
; 48(8): 2642-2651, 2021 07.
Article
in English
| MEDLINE | ID: mdl-33495926
12.
Combined use of 177Lu-DOTATATE and metronomic capecitabine (Lu-X) in FDG-positive gastro-entero-pancreatic neuroendocrine tumors.
Eur J Nucl Med Mol Imaging
; 48(10): 3260-3267, 2021 09.
Article
in English
| MEDLINE | ID: mdl-33604690
13.
Imaging of neuroendocrine tumors: A pictorial review of the clinical value of different imaging modalities.
Rev Endocr Metab Disord
; 22(3): 539-552, 2021 09.
Article
in English
| MEDLINE | ID: mdl-33783695
14.
Molecular profiling of neuroendocrine tumours to predict response and toxicity to peptide receptor radionuclide therapy.
Lancet Oncol
; 21(9): e431-e443, 2020 09.
Article
in English
| MEDLINE | ID: mdl-32888472
15.
Lessons from a multicentre retrospective study of peptide receptor radionuclide therapy combined with lanreotide for neuroendocrine tumours: a need for standardised practice.
Eur J Nucl Med Mol Imaging
; 47(10): 2358-2371, 2020 09.
Article
in English
| MEDLINE | ID: mdl-32062681
16.
Comparison of 68Ga-DOTA-JR11 PET/CT with dosimetric 177Lu-satoreotide tetraxetan (177Lu-DOTA-JR11) SPECT/CT in patients with metastatic neuroendocrine tumors undergoing peptide receptor radionuclide therapy.
Eur J Nucl Med Mol Imaging
; 47(13): 3047-3057, 2020 12.
Article
in English
| MEDLINE | ID: mdl-32378020
17.
PRRT neuroendocrine tumor response monitored using circulating transcript analysis: the NETest.
Eur J Nucl Med Mol Imaging
; 47(4): 895-906, 2020 04.
Article
in English
| MEDLINE | ID: mdl-31838581
18.
Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with 177Lu-Dotatate: an analysis of the NETTER-1 study.
Eur J Nucl Med Mol Imaging
; 47(10): 2372-2382, 2020 09.
Article
in English
| MEDLINE | ID: mdl-32123969
19.
An Assessment of Circulating Chromogranin A as a Biomarker of Bronchopulmonary Neuroendocrine Neoplasia: A Systematic Review and Meta-Analysis.
Neuroendocrinology
; 110(3-4): 198-216, 2020.
Article
in English
| MEDLINE | ID: mdl-31266019
20.
Neuroendocrine Neoplasms of the Small Bowel and Pancreas.
Neuroendocrinology
; 110(6): 444-476, 2020.
Article
in English
| MEDLINE | ID: mdl-31557758